Nanobiotix

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Nanobiotix is a clinical-stage company pioneering new approaches to change patient outcomes, bringing nanophysics to the heart of the cell.

It's lead compound, NBTXR3, is a first-in-class product designed to enhance the effect of radiation within the tumor cells, causing physical cell death.

NBTXR3 has a physical MoA that translates into a tumor agnostic approach. It has also shown evidence of improved immune activation and synergy in IO combination models.

NBTXR3 has been approved in Europe for soft tissue sarcomas. Additionally, as a single agent, NBTXR3 is being explored in cancers including H&N, prostate, and HCC. NBTXR3 is also being explored in combination with anti-PD1s. Nanobiotix also has a large-scale, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to evaluate NBTXR3 in various other solid tumors.

FDA recently granted Nanobiotix a Fast Track Designation for NBTXR3 in Head and Neck Cancer.
Ticker:
NANO
Exchange:
Euronext
Company Type:
Not Provided
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
France
Year Founded:
2003
Main Therapeutic Focus:
Lead Product in Development:
NBTXR3
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO Nanobiotix USA & Global Head of Business Development
Nanobiotix